Evogene Ltd. (EVGN) was a big mover last session, as the company saw its shares rise over 10% on the day. The upside has been driven by the announcement that the company’s recently developed comprehensive gene optimization program is being incorporated into its multi-year collaboration with Monsanto Company (MON). This led to more shares changing hands than in a normal session. Yesterday’s rally breaks the trend for the company since Jan 22, as the stock is now trading above the volatile price range of $8.20 to $8.51.
Over the last 30 days, this biopharmaceutical company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Evogene currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment